Peptide Library

Human study PLS-00234

A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

Other design · 308 participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failureregistry entry · NCT02914665 (COMPLETED, no results posted, planned enrollment 308)

Design and participants

Design
Other design
Population
Patients hospitalized with congestion due to heart failure
Conditions
Heart Failure
Setting
Hospital (inpatients hospitalized with heart failure congestion)
Planned enrollment (registry)
308
Enrolled
308
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • Elamipretide (intervention) · elamipretide · Elamipretide (also listed as MTP-131, Bendavia); short-term treatment · Short term treatment (per title) · Not reported assigned
  • Placebo (comparator) · Placebo · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • other: The record does not state the allocation method or blinding. It lists only a placebo intervention, so randomization cannot be confirmed.
  • selective reporting: The study is completed with an actual enrollment of 308, yet no results are posted in the registry record provided.
  • inappropriate population: The population is heart failure patients hospitalized with congestion. It does not match Barth syndrome or primary mitochondrial myopathy.
  • short follow up: The title describes short-term treatment only, and no follow-up duration is given in the record.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: NCT NCT02914665, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT02914665, registry (phases, study_type, interventions fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT02914665, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT02914665, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT02914665, title (study title) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).